Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
The present invention relates to novel crystalline forms of ACP-196 (acalabrutinib) salts, compared with the known solid form of ACP-196, the crystalline forms of ACP-196 salts of the present invention have advantages in crystallinity, solubility and hygroscopicity. The present invention also relates to the preparation methods for the preparation of the crystalline forms of ACP-196 salts, pharmaceutical compositions thereof and their uses in the preparation of methods for treating and/or preventing diseases mediated by Bruton tyrosine kinase (BTK), such as autoimmune diseases or disorders, xenoimmune diseases or disorders, cancer, including lymphoma and inflammatory diseases or disorders.
1. ACP-196 malate Form 1 having the structure shown in the formula (I) below,
wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the ACP-196 malate Form 1, expressed as 2θ angles, has the following characteristic peaks: 6.2°±0.2°, 8.9°±0.2°, 12.0°±0.2°, 12.4°±0.2°, 16.9°±0.2° and 22.9°±0.2°.
2. The ACP-196 malate Form 1 according to claim 1 , wherein the X-ray powder diffraction pattern of the ACP-196 malate Form 1, expressed as 2θ angles, has the following characteristic peaks: 6.2°±0.2°, 8.9°±0.2°, 12.0°±0.2°, 12.4°±0.2°, 15.6°±0.2°, 16.9°±0.2°, 19.6°±0.2° 20.3°±0.2°, 20.7°±0.2°, 22.9°±0.2°, 23.8°±0.2° and 27.6°±0.2°.
3. The ACP-196 malate Form 1 according to claim 2 , wherein the X-ray powder diffraction pattern of the ACP-196 malate Form 1, expressed as 2θ angles, has the following characteristic peaks and relative intensity:
Diffraction angel 2θ
Relative intensity %
6.2° ± 0.2°
81.9
8.9° ± 0.2°
21.3
12.0° ± 0.2°
70.1
12.4° ± 0.2°
100.0
12.9° ± 0.2°
8.7
15.6° ± 0.2°
12.5
16.9° ± 0.2°
22.5
17.9° ± 0.2°
10.9
18.7° ± 0.2°
7.7
19.6° ± 0.2°
21.5
20.3° ± 0.2°
16.3
20.7° ± 0.2°
16.9
21.2° ± 0.2°
10.7
22.9° ± 0.2°
32.7
23.8° ± 0.2°
28.8
24.9° ± 0.2°
12.1
26.3° ± 0.2°
9.7
27.6° ± 0.2°
17.6.
4. A method of preparing the ACP-196 malate Form 1 according to claim 1 , comprising any one of the following methods:
1) dissolving ACP-196 and malic acid respectively in a solvent to form solutions, then mixing and stirring for crystallization and precipitation, and then separating and drying to obtain the ACP-196 malate Form 1; wherein:
the solvent is an alcohol or a ketone;
the weight to volume ratio of ACP-196 to the solvent when the solution is formed is from 30 mg/mL to 100 mg/mL;
the molar ratio of ACP-196 to malic acid is from 1:0.8 to 1:1.1;
the stirring time is 1 day to 2 days; and
the operation is carried out at room temperature; or
2) forming a solution of a mixture of ACP-196 and malic acid in a co-solvent, adding anti-solvent, stirring for crystallization and precipitation, and then separating and drying to obtain the ACP-196 malate Form 1; wherein:
the co-solvent is selected from the group consisting of ethyl acetate, isopropyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, and chloroform;
the weight to volume ratio of ACP-196 to the co-solvent is from 20 mg/mL to 100 mg/mL;
the molar ratio of ACP-196 to malic acid is from 1:0.8 to 1:1.1;
the anti-solvent is selected from the group consisting of an ether, an alkane, and toluene;
the stirring time is from 1 day to 3 days; and
the operation is carried out at room temperature.
5. The method according to claim 4 , wherein the solvent is isopropanol and wherein the weight to volume ratio of ACP-196 to the solvent is from 30 mg/mL to 50 mg/mL.
6. The method according to claim 4 , wherein the co-solvent is tetrahydrofuran and wherein the weight to volume ratio of ACP-196 to the co-solvent is from 20 mg/mL to 50 mg/mL.
7. The method according to claim 4 , wherein the anti-solvent is isopropyl ether.
8. The method according to claim 4 , wherein ACP-196 and malic acid use the same solvent to form a solution.
9. A pharmaceutical composition comprising a therapeutically effective amount of the ACP-196 malate Form 1 according to claim 1 , and at least one pharmaceutically acceptable carrier or additive.
10. A method of preparing the ACP-196 sulfate Form 1 having the structure shown in the formula (V) below,
wherein, measured using Cu-Kα radiation, the X-ray powder diffraction pattern of the ACP-196 sulfate Form 1, expressed as 2θ angles, has the following characteristic peaks: 8.9°±0.2°, 9.7°±0.2°, 17.5°±0.2°, 19.6°±0.2°, 21.9°±0.2°, and 23.6°±0.2°, the method comprising any one of the following methods:
1) dissolving ACP-196 and sulfuric acid respectively in a solvent to form solutions, then mixing and stirring for crystallization and precipitation, and then separating and drying to obtain the ACP-196 sulfate Form 1; wherein:
the solvent is an alcohol or a ketone;
the weight to volume ratio of ACP-196 to the solvent when the solution is formed is from 30 mg/mL to 100 mg/mL;
the molar ratio of ACP-196 to sulfuric acid is from 1:0.8 to 1:1.1;
the stirring time is 1 day to 2 days; and
the operation is carried out at room temperature; or
2) forming a solution of ACP-196 in a co-solvent, dropwisely adding sulfuric acid and anti-solvent, stirring for crystallization and precipitation, and then separating and drying to obtain the ACP-196 sulfate Form 1; wherein:
the co-solvent is selected from the group consisting of ethyl acetate, isopropyl acetate, tetrahydrofuran, 1,4-dioxane, acetonitrile, dichloromethane, and chloroform;
the weight to volume ratio of ACP-196 to the co-solvent is from 10 mg/mL to 500 mg/mL;
the molar ratio of ACP-196 to sulfuric acid is from 1:0.8 to 1:1.1;
the anti-solvent is selected from the group consisting of an ether, an alkane, and toluene;
the stirring time is from 1 day to 3 days; and
the operation is carried out at room temperature,
wherein the solvent is isopropanol and wherein the weight to volume ratio of ACP-196 to the solvent is from 30 mg/mL to 50 mg/mL.
11. The method according to claim 10 , wherein the co-solvent is ethyl acetate and wherein the weight to volume ratio of ACP-196 to the co-solvent is from 25 mg/mL to 50 mg/mL.
12. The method according to claim 10 , wherein the anti-solvent is n-hexane.
13. The method according to claim 10 , wherein the X-ray powder diffraction pattern of the ACP-196 sulfate Form 1, expressed as 2θ angles, has the following characteristic peaks: 4.6°±0.2°, 7.9°±0.2°, 8.9°±0.2°, 9.7°±0.2°, 14.6°±0.2°, 15.0°±0.2°, 17.5°±0.2°, 19.6°±0.2°, 20.0°±0.2°, 21.9°±0.2°, 23.6°±0.2° and 25.9°±0.2°.
14. The method according to claim 13 , wherein the X-ray powder diffraction pattern of the ACP-196 sulfate Form 1, expressed as 2θ angles, has the following characteristic peaks and relative intensity:
Diffraction angel 2θ
Relative intensity %
4.6° ± 0.2°
21.6
7.9° ± 0.2°
14.2
8.9° ± 0.2°
41.9
9.7° ± 0.2°
70.4
14.6° ± 0.2°
21.2
15.0° ± 0.2°
20.7
17.5° ± 0.2°
100.0
17.8° ± 0.2°
47.5
19.6° ± 0.2°
50.7
20.0° ± 0.2°
31.4
21.9° ± 0.2°
59.7
23.6° ± 0.2°
53.3
24.3° ± 0.2°
31.8
24.8° ± 0.2°
18.5
25.6° ± 0.2°
27.9
25.9° ± 0.2°
33.4
27.1° ± 0.2°
16.0
27.5° ± 0.2°
13.2
28.0° ± 0.2°
8.2
29.2° ± 0.2°
26.7
30.2° ± 0.2°
11.1
31.6° ± 0.2°
13.3.